Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishing minimal clinically important difference of modified dynamic gait index in people with subacute stroke.
Mestanza Mattos FG, Bowman T, Allera Longo C, Bocini S, Gennuso M, Marazzini F, Materazzi FG, Pelosin E, Putzolu M, Salvalaggio S, Turolla A, Mezzarobba S, Cattaneo D. Mestanza Mattos FG, et al. Among authors: turolla a. Top Stroke Rehabil. 2025 Jan 7:1-5. doi: 10.1080/10749357.2024.2437326. Online ahead of print. Top Stroke Rehabil. 2025. PMID: 39773201
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
Anand R, Turolla A, Chinellato G, Sansi F, Roy A, Hartman R. Anand R, et al. Among authors: turolla a. Neuropharmacology. 2024 Dec 19;266:110275. doi: 10.1016/j.neuropharm.2024.110275. Online ahead of print. Neuropharmacology. 2024. PMID: 39708914 Free article.
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Anand R, et al. Among authors: turolla a. Int J Neuropsychopharmacol. 2024 Dec 28;28(1):pyae061. doi: 10.1093/ijnp/pyae061. Int J Neuropsychopharmacol. 2024. PMID: 39661380 Free PMC article. Clinical Trial.
The minimally clinically important difference in the 2-minute walk test for people in the subacute phase after a stroke.
Bowman T, Mestanza Mattos FG, Allera Longo C, Bocini S, Gennuso M, Marazzini F, Giuseppe Materazzi F, Pelosin E, Putzolu M, Salvalaggio S, Turolla A, Mezzarobba S, Cattaneo D. Bowman T, et al. Among authors: turolla a. Top Stroke Rehabil. 2024 Nov 11:1-9. doi: 10.1080/10749357.2024.2417643. Online ahead of print. Top Stroke Rehabil. 2024. PMID: 39527092 Free article.
Predictive factors and dose-response effect of rehabilitation for upper limb induced recovery after stroke: systematic review with proportional meta-analyses.
Salvalaggio S, Gianola S, Andò M, Cacciante L, Castellini G, Lando A, Ossola G, Pregnolato G, Rutkowski S, Vedovato A, Zandonà C, Turolla A. Salvalaggio S, et al. Among authors: turolla a. Physiotherapy. 2024 Dec;125:101417. doi: 10.1016/j.physio.2024.101417. Epub 2024 Aug 3. Physiotherapy. 2024. PMID: 39395360 Review.
167 results